Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 14, 2006 David Meier	Individual Investors Unite! In this interview with chief investment strategist at Legg Mason and author of the new book More Than You Know, Michael Mauboussin talks about the advantages you and I have over institutional investors.
The Motley Fool November 4, 2009 Brian Orelli	This One Is Thriving in a Recession Saving customers money makes it easy for Medco.
The Motley Fool August 31, 2011 Shubh Datta	CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue.
The Motley Fool July 7, 2006 David Meier	Is It Luck or Skill? Generating high returns isn't purely a question of skill; it requires some luck, too. Which factor determines investing success? Here's some advice from Michael Mauboussin, chief investment strategist at Legg Mason and author of More Than You Know.
The Motley Fool July 10, 2006 David Meier	Survive the Investment Race Michael Mauboussin, chief investment strategist at Legg Mason and author of More Than You Know, shares his insights on how to be a successful long-term investor.
The Motley Fool June 30, 2011 David Williamson	Pharmacy Benefits Delivering Drama CVS claims another Medco client and one messy split.
The Motley Fool May 4, 2011 Jason Knapp	Generic Drugs and Old People Could Make You Rich CVS hasn't generated market-beating returns yet -- but it will.
The Motley Fool March 22, 2010 Dave Mock	A Big Upgrade for CVS Caremark This bullish call comes from more than just one analyst.
The Motley Fool November 2, 2006 Ryan Fuhrmann	CVS Blazes a New Healthcare Trail Strong third-quarter earnings aside, the merger announcement with pharmacy benefit manager Caremark was the real shocker here. Investors, take note.
The Motley Fool February 25, 2009 Brian Orelli	The Best Kind of Generic Growth Pharmacy benefit managers profit from penny-pinchers.
The Motley Fool September 26, 2006 Ryan Fuhrmann	Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers?
The Motley Fool December 19, 2006 Matthew Crews	Express Scripts' Takeover Battle The pharmacy benefits manager challenges CVS with a higher bid for rival Caremark RX. Investors, stay tuned -- this is far from over.
The Motley Fool December 6, 2007 Selena Maranjian	Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall.
The Motley Fool January 7, 2010 Gerard Torres	Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition.
The Motley Fool April 29, 2010 Brian Orelli	A Prescription to Investigate Further Let's not worry just yet about Medco's margins.
The Motley Fool October 6, 2011 Dan Caplinger	Has Medco Health Solutions Become the Perfect Stock? A lot has happened in the pharmacy benefits management space since we looked at Medco last year.
The Motley Fool November 14, 2006 Nathan Parmelee	Time to Love Wal-Mart Again Some pretty handsome returns can be earned by investors who pick up the retailer's shares on the days when there is bad news and hold patiently for a few years.
The Motley Fool February 24, 2005 David Meier	Got Value? Value investing is the best way to play. Is it in you? As an investor, your goal is to have your investments outperform the market. Have you got value to help you achieve them?
The Motley Fool September 22, 2006 Ryan Fuhrmann	More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note.
The Motley Fool July 27, 2004 Brian Gorman	Medco's Pumped About Generics Generic drugs are actually helping improve Medco's margins, making it a winner with investors and health-care plans.
The Motley Fool March 28, 2005 Brian Gorman	A Passage to India? Changes in India's patent law could create new dynamics for the biotech and pharmaceutical industries. Investors should be on the lookout for the firms that seek to leverage these new opportunities.
The Motley Fool June 14, 2007 Mac Greer	Fool Video: Dell: Buy, Sell, or Hold? The PC maker recently reported better-than-expected earnings, but it also announced that it will lay off 8,000 employees. What should investors make of the latest news?
The Motley Fool August 16, 2010 Brian Orelli	The Fine Line Between Saving Money and Making It Medco's trying to walk it.
The Motley Fool February 2, 2005 Alyce Lomax	CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny.
The Motley Fool October 2, 2011 Shubh Datta	Would You Invest in This Drug Retailer? Is CVS Caremark worth your investment?
The Motley Fool August 3, 2007 Ryan Fuhrmann	CVS Caremark Is No Sicko Pharmacy powerhouse CVS Caremark is looking to blaze a new health-care trail with the recent merger of their drugstore and pharmacy benefit management operations.
The Motley Fool November 9, 2006 Mike Norman	CVS-Caremark Not So Hard to Swallow Huge demographic and policy trends are likely to make this match a winner. Why did investors sell CVS?
The Motley Fool February 14, 2005 Brian Gorman	GM Pulls Out of Walgreen The pharmacy's mail-order policy spurs the automaker's cost-containment decision.
The Motley Fool February 17, 2005 Stephen D. Simpson	Caremark Hits the Mark Again With expectations of higher than 25% growth in 2005, the pharmacy benefits manager looks like it will continue to take care of its investors.
The Motley Fool August 1, 2006 Selena Maranjian	Prescription for Prescription Bargains Did you know that your medications might be cheaper around the corner? Another way to offset your net expenses on medications is to make some money on drugs -- by investing in drug-related firms.
The Motley Fool May 8, 2007 Ryan Fuhrmann	CVS/Caremark Tie the Knot While it's too early to see if CVS blazed a new health-care trail by combining a drugstore chain with giant pharmacy benefit manager Caremark, there are still interesting tidbits to pass along to investors from recently reported results.
The Motley Fool January 3, 2005 Nathan Slaughter	Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.
The Motley Fool August 15, 2007 Mary Dalrymple	Drug Costs Giving You a Headache? If you want to cut your prescription drug costs, you can do more than just switch to generic brands. Shop around and ask questions. It's your health, and it's your money.
The Motley Fool July 20, 2009 Jennifer Schonberger	The Biggest Mistake Value Investors Make Legg Mason's Michael Mauboussin speaks on market psychology and value investing.
The Motley Fool February 16, 2005 Brian Gorman	Medco's Double-Edged Sword The pharmacy benefit manager's latest financial report indicates that its business remains robust. But is it at the expense of retail pharmacies?
The Motley Fool August 20, 2004 Matt Logan	Value in a Diverse Team Legg Mason's Mary Chris Gay talks about the value of a diverse investment team, names her favorite investors, and lists five stock picks for the next 10 years.
The Motley Fool June 26, 2007 Ryan Fuhrmann	Walgreen Sells Convenience Walgreen continues to grow market share, with little sign of slowing down.
The Motley Fool January 8, 2007 Matthew Crews	CVS' Tightrope Walk The drugstore chain's aggressive growth strategy continues to pay off -- for now. Investors, take note.
The Motley Fool August 8, 2005 Mike Cianciolo	A Cautiously Optimistic CVS The retail pharmacy nudges guidance up after an impressive quarter. All things considered, the outlook seems bright for investors in this company.
The Motley Fool November 3, 2011	A Brief History of Walgreen's Returns Walgreen's P/E ratio declined by more than 70% over the past 10 years. That's simply incredible. Every bit of Walgreen's earnings growth has been discounted by the market through lower valuations.
The Motley Fool October 24, 2006 Brian Gorman	Medco's Fringe Benefits Recent developments will present some challenges, but Medco remains a solid long-term investment.
The Motley Fool September 15, 2006 Jack Uldrich	Foolish Book Review: "More Than You Know" Michael Mauboussin's new book shows how you can do more than crunch numbers to become a better investor.
The Motley Fool March 24, 2008 Timothy M. Otte	Expecting More From Walgreen The drugstore giant has managed to beat analyst estimates two quarters in a row, but earnings are lagging sales growth, and growth is slowing too.
The Motley Fool July 12, 2006 David Meier	Better Decisions, Better Returns An interview with Michael Mauboussin, chief investment strategist at Legg Mason and author of More Than You Know about the decision-making biases that are chronically hurting your portfolio, and how to combat them.
The Motley Fool March 26, 2007 Ryan Fuhrmann	Addicted to Growth at Walgreen Walgreen is a steady grower, but that comes at a price. Investors, take note.
The Motley Fool June 2, 2011 Dee Gill	CVS's Improved Performance Begins to Drown Out the Dump-Caremark Chants Is the prognosis for CVS looking up?
The Motley Fool August 1, 2007 Ryan Fuhrmann	Foolish Forecast: CVS Caremark Gets Ready to Rumble CVS Caremark will announce its first combined quarterly results tomorrow. Competitors will be watching to see if the merger of drugstore chain and pharmacy benefit manager is a healthy one.
The Motley Fool November 3, 2010 Brian Orelli	A Generic Prescription for Double-Digit Growth MedcoHealth Solutions has it.
The Motley Fool November 9, 2005 Brian Gorman	Caremark's Room to Grow Fickle investors may fret about near-term growth, but the pharmacy benefit manager is prepared for the long haul. Investors looking for a long-term holding may want to mark a place in their portfolio for this company.
The Motley Fool February 15, 2006 Stephen D. Simpson	Good Marks for Caremark The pharmacy benefits management company should have even more positive operating leverage left in the tank. Investors, take note.